-
-
-
-
-
-
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Barclays
-
-
-
-
-
-
-
BioMarin plans $850 million bond offering to fund Amicus acquisition
-
-
-
-
-
-
-
Leerink Partners Downgrades BioMarin Pharmaceutical Inc. (BMRN) to Market Perform
-
-
-
-
-
-
-
BioMarin Announces Completion of Acquisition of Inozyme
-
-
-
-
-
-
-
Bernstein provides 2025 M&A outlook for U.S. Biotech and Pharma
-
-
-
-
-
-
-
BioMarin Pharma (BMRN) Announces FDA Approves ROCTAVIAN, the First and Only Gene Therapy for Adults with Severe Hemophilia A
-
-
-
-
-
-
-
Roche to complete $4.3 billion Spark deal as regulators give all clear
-
1,158,425 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

